Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RHEB | Q15382 | 3/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7880796 | 0.90 | ALDH1A1 (0.32) | ALDH1A1MAPTRHEB | |
| SCHEMBL7879914 | 0.88 | ALDH1A1 (0.31) | ALDH1A1MAPTRHEB | |
| SCHEMBL7882066 | 0.88 | TDP1 (0.34) | MAPTRHEBGRIN1EIF4A3 | |
| SCHEMBL7881877 | 0.87 | RHEB (0.34) | RHEB | |
| SCHEMBL7879832 | 0.87 | KDM4E (0.35) | ALDH1A1MAPTRHEB | |
| SCHEMBL7873486 | 0.85 | KMT2A (0.36) | — | |
| SCHEMBL7884369 | 0.84 | RHEB (0.33) | RHEBGRIN1EIF4A3 | |
| SCHEMBL7879412 | 0.83 | RHEB (0.39) | RHEBGRIN1EIF4A3 | |
| Hydrochloric Acid SCHEMBL7881148 | 0.83 | RHEB (0.39) | RHEBGRIN1EIF4A3 | |
| SCHEMBL7880770 | 0.81 | CYP3A4 (0.40) | RHEBGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |